Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 12/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876930 | 0.85 | P2RY12 (0.49) | P2RY12OPRK1CYP3A4CYP2C9KDM4E | |
| SCHEMBL4878784 | 0.85 | P2RY12 (0.45) | P2RY12OPRK1CYP3A4CYP2C9OPRM1 | |
| SCHEMBL3221673 | 0.82 | P2RY12 (0.69) | P2RY12CYP3A4CYP2C9KDM4EHSD17B10 | |
| SCHEMBL5592386 | 0.77 | P2RY12 (0.63) | P2RY12CYP3A4CYP2C9KDM4E | |
| SCHEMBL5014112 | 0.77 | P2RY12 (0.63) | P2RY12CYP3A4CYP2C9KDM4E | |
| SCHEMBL5014008 | 0.76 | P2RY12 (0.62) | P2RY12CYP3A4CYP2C9KDM4E | |
| SCHEMBL3328558 | 0.75 | P2RY12 (0.56) | P2RY12CYP3A4CYP2C9KDM4EALDH1A1 | |
| SCHEMBL4881142 | 0.74 | MEN1 (0.45) | P2RY12OPRK1KDM4EALDH1A1TSHR | |
| SCHEMBL30999839 | 0.74 | P2RY12 (0.65) | P2RY12CYP3A4CYP2C9 | |
| SCHEMBL29258844 | 0.74 | P2RY12 (0.65) | P2RY12CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885OPRK1 1862/4885CYP3A4 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.